Closing the production gap in gene therapy – A scalable helper virus-free AAV production platform

Thursday, July 11th ; 08:00 PST; 11:00 EST; 16:00 BST; 17:00 CST

With gene therapy projects moving towards more common diseases, such as Rheumatoid Arthritis, Parkinson´s disease or Alzheimer´s disease, there is a growing need for large-scale viral vector production, in particular for adeno-associated viral (AAV) vectors. However, current production systems rely on transient plasmid transfection or helper viruses and are thus hardly scalable. The webinar will address solutions to overcome this production gap in gene therapy.
  • Learn how CEVEC´s stable, helper virus-free AAV platform overcomes scalability issues by moving AAV production to stable producer cells.
Nicole Faust
CEVEC Pharmaceuticals GmbH
View Biography
Clive Glover
Director, Strategy
Pall Biotech
View Biography
Dr Andy Topping
Chief Scientific Officer
FUJIFILM Diosynth Biotechnologies
View Biography
Philip Wills
Chief Commercial Officer
Paragon Bioservices, Inc
View Biography

Registration Details:

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.

(*) denotes required form field(s)